世界のクロモブラストミコーシス（CBM）治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Chromoblastomycosis Treatment Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z1309
• 出版社/出版日：QYResearch / 2021年4月
※2025年版があります。お問い合わせください。
• レポート形態：英文、PDF、91ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査資料では、クロモブラストミコーシス（CBM）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（診断、治療）、用途別市場規模（病院、クリニック）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。
・市場概要
・クロモブラストミコーシス（CBM）治療の市場動向
・企業の競争状況、市場シェア
・クロモブラストミコーシス（CBM）治療の種類別市場規模（診断、治療）
・クロモブラストミコーシス（CBM）治療の用途別市場規模（病院、クリニック）
・クロモブラストミコーシス（CBM）治療の北米市場規模2016-2027（アメリカ、カナダ）
・クロモブラストミコーシス（CBM）治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等）
・クロモブラストミコーシス（CBM）治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・クロモブラストミコーシス（CBM）治療の中南米市場規模2016-2027（メキシコ、ブラジル）
・クロモブラストミコーシス（CBM）治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Astellas Pharma、Biocon、Abbott Laboratories、Merck、Gilead Sciences、Mylan Labs、Bayer、Lonza Group、Sanofi、Roche、Cadila Pharmaceuticals、Johnson & Johnson、Pfizer、Novartis）
・結論

Chromoblastomycosis is a fungal infection caused by species such as Fonsecaea pedrosoi, Cladophialophora carrionii, Phialophora verrucosa, Fonsecaea compacta, Rhinocladiella aquaspersa, Chaetomium funicola and others. This disease mostly affects the skin and the subcutaneous tissues. Globally, there is about a million type of fungal species, yet nearly 300 are capable of causing infections or disease in humans. Most of these cases are seen in people with compromised immune systems and can occur almost in any part of the body.
A type of fungal infection known as systemic mycosis is affecting the internal organs of the body. During this, fungal infection can spread and affect other organs of the body. The rising cases of immunological diseases is a reason for increased probability of systemic mycosis. Thus, the developing novel treatment for chromoblastomycosis with fewer side effects is the primary objective of manufacturing companies.

Market Analysis and Insights: Global Chromoblastomycosis Treatment Market
The global Chromoblastomycosis Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Chromoblastomycosis Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Chromoblastomycosis Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Chromoblastomycosis Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Chromoblastomycosis Treatment market.

Global Chromoblastomycosis Treatment Scope and Market Size
Chromoblastomycosis Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Chromoblastomycosis Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Diagnosis
Treatment

Segment by Application
Hospitals
Clinics

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Astellas Pharma
Biocon
Abbott Laboratories
Merck
Gilead Sciences
Mylan Labs
Bayer
Lonza Group
Sanofi
Merck
Gilead Sciences
Johnson & Johnson

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chromoblastomycosis Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Diagnosis
1.2.3 Treatment
1.3 Market by Application
1.3.1 Global Chromoblastomycosis Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Chromoblastomycosis Treatment Market Perspective (2016-2027)
2.2 Chromoblastomycosis Treatment Growth Trends by Regions
2.2.1 Chromoblastomycosis Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Chromoblastomycosis Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Chromoblastomycosis Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Chromoblastomycosis Treatment Industry Dynamic
2.3.1 Chromoblastomycosis Treatment Market Trends
2.3.2 Chromoblastomycosis Treatment Market Drivers
2.3.3 Chromoblastomycosis Treatment Market Challenges
2.3.4 Chromoblastomycosis Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Chromoblastomycosis Treatment Players by Revenue
3.1.1 Global Top Chromoblastomycosis Treatment Players by Revenue (2016-2021)
3.1.2 Global Chromoblastomycosis Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Chromoblastomycosis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Chromoblastomycosis Treatment Revenue
3.4 Global Chromoblastomycosis Treatment Market Concentration Ratio
3.4.1 Global Chromoblastomycosis Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chromoblastomycosis Treatment Revenue in 2020
3.5 Chromoblastomycosis Treatment Key Players Head office and Area Served
3.6 Key Players Chromoblastomycosis Treatment Product Solution and Service
3.7 Date of Enter into Chromoblastomycosis Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Chromoblastomycosis Treatment Breakdown Data by Type
4.1 Global Chromoblastomycosis Treatment Historic Market Size by Type (2016-2021)
4.2 Global Chromoblastomycosis Treatment Forecasted Market Size by Type (2022-2027)

5 Chromoblastomycosis Treatment Breakdown Data by Application
5.1 Global Chromoblastomycosis Treatment Historic Market Size by Application (2016-2021)
5.2 Global Chromoblastomycosis Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Chromoblastomycosis Treatment Market Size (2016-2027)
6.2 North America Chromoblastomycosis Treatment Market Size by Type
6.2.1 North America Chromoblastomycosis Treatment Market Size by Type (2016-2021)
6.2.2 North America Chromoblastomycosis Treatment Market Size by Type (2022-2027)
6.2.3 North America Chromoblastomycosis Treatment Market Size by Type (2016-2027)
6.3 North America Chromoblastomycosis Treatment Market Size by Application
6.3.1 North America Chromoblastomycosis Treatment Market Size by Application (2016-2021)
6.3.2 North America Chromoblastomycosis Treatment Market Size by Application (2022-2027)
6.3.3 North America Chromoblastomycosis Treatment Market Size by Application (2016-2027)
6.4 North America Chromoblastomycosis Treatment Market Size by Country
6.4.1 North America Chromoblastomycosis Treatment Market Size by Country (2016-2021)
6.4.2 North America Chromoblastomycosis Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Chromoblastomycosis Treatment Market Size (2016-2027)
7.2 Europe Chromoblastomycosis Treatment Market Size by Type
7.2.1 Europe Chromoblastomycosis Treatment Market Size by Type (2016-2021)
7.2.2 Europe Chromoblastomycosis Treatment Market Size by Type (2022-2027)
7.2.3 Europe Chromoblastomycosis Treatment Market Size by Type (2016-2027)
7.3 Europe Chromoblastomycosis Treatment Market Size by Application
7.3.1 Europe Chromoblastomycosis Treatment Market Size by Application (2016-2021)
7.3.2 Europe Chromoblastomycosis Treatment Market Size by Application (2022-2027)
7.3.3 Europe Chromoblastomycosis Treatment Market Size by Application (2016-2027)
7.4 Europe Chromoblastomycosis Treatment Market Size by Country
7.4.1 Europe Chromoblastomycosis Treatment Market Size by Country (2016-2021)
7.4.2 Europe Chromoblastomycosis Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Chromoblastomycosis Treatment Market Size (2016-2027)
8.2 Asia-Pacific Chromoblastomycosis Treatment Market Size by Type
8.2.1 Asia-Pacific Chromoblastomycosis Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Chromoblastomycosis Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Chromoblastomycosis Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Chromoblastomycosis Treatment Market Size by Application
8.3.1 Asia-Pacific Chromoblastomycosis Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Chromoblastomycosis Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Chromoblastomycosis Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Chromoblastomycosis Treatment Market Size by Region
8.4.1 Asia-Pacific Chromoblastomycosis Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Chromoblastomycosis Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Chromoblastomycosis Treatment Market Size (2016-2027)
9.2 Latin America Chromoblastomycosis Treatment Market Size by Type
9.2.1 Latin America Chromoblastomycosis Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Chromoblastomycosis Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Chromoblastomycosis Treatment Market Size by Type (2016-2027)
9.3 Latin America Chromoblastomycosis Treatment Market Size by Application
9.3.1 Latin America Chromoblastomycosis Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Chromoblastomycosis Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Chromoblastomycosis Treatment Market Size by Application (2016-2027)
9.4 Latin America Chromoblastomycosis Treatment Market Size by Country
9.4.1 Latin America Chromoblastomycosis Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Chromoblastomycosis Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Chromoblastomycosis Treatment Market Size (2016-2027)
10.2 Middle East & Africa Chromoblastomycosis Treatment Market Size by Type
10.2.1 Middle East & Africa Chromoblastomycosis Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Chromoblastomycosis Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Chromoblastomycosis Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Chromoblastomycosis Treatment Market Size by Application
10.3.1 Middle East & Africa Chromoblastomycosis Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Chromoblastomycosis Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Chromoblastomycosis Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Chromoblastomycosis Treatment Market Size by Country
10.4.1 Middle East & Africa Chromoblastomycosis Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Chromoblastomycosis Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Astellas Pharma
11.1.1 Astellas Pharma Company Details
11.1.2 Astellas Pharma Business Overview
11.1.3 Astellas Pharma Chromoblastomycosis Treatment Introduction
11.1.4 Astellas Pharma Revenue in Chromoblastomycosis Treatment Business (2016-2021)
11.1.5 Astellas Pharma Recent Development
11.2 Biocon
11.2.1 Biocon Company Details
11.2.2 Biocon Business Overview
11.2.3 Biocon Chromoblastomycosis Treatment Introduction
11.2.4 Biocon Revenue in Chromoblastomycosis Treatment Business (2016-2021)
11.2.5 Biocon Recent Development
11.3 Abbott Laboratories
11.3.1 Abbott Laboratories Company Details
11.3.2 Abbott Laboratories Business Overview
11.3.3 Abbott Laboratories Chromoblastomycosis Treatment Introduction
11.3.4 Abbott Laboratories Revenue in Chromoblastomycosis Treatment Business (2016-2021)
11.3.5 Abbott Laboratories Recent Development
11.4 Merck
11.4.1 Merck Company Details
11.4.2 Merck Business Overview
11.4.3 Merck Chromoblastomycosis Treatment Introduction
11.4.4 Merck Revenue in Chromoblastomycosis Treatment Business (2016-2021)
11.4.5 Merck Recent Development
11.5 Gilead Sciences
11.5.1 Gilead Sciences Company Details
11.5.2 Gilead Sciences Business Overview
11.5.3 Gilead Sciences Chromoblastomycosis Treatment Introduction
11.5.4 Gilead Sciences Revenue in Chromoblastomycosis Treatment Business (2016-2021)
11.5.5 Gilead Sciences Recent Development
11.6 Mylan Labs
11.6.1 Mylan Labs Company Details
11.6.2 Mylan Labs Business Overview
11.6.3 Mylan Labs Chromoblastomycosis Treatment Introduction
11.6.4 Mylan Labs Revenue in Chromoblastomycosis Treatment Business (2016-2021)
11.6.5 Mylan Labs Recent Development
11.7 Bayer
11.7.1 Bayer Company Details
11.7.2 Bayer Business Overview
11.7.3 Bayer Chromoblastomycosis Treatment Introduction
11.7.4 Bayer Revenue in Chromoblastomycosis Treatment Business (2016-2021)
11.7.5 Bayer Recent Development
11.8 Lonza Group
11.8.1 Lonza Group Company Details
11.8.2 Lonza Group Business Overview
11.8.3 Lonza Group Chromoblastomycosis Treatment Introduction
11.8.4 Lonza Group Revenue in Chromoblastomycosis Treatment Business (2016-2021)
11.8.5 Lonza Group Recent Development
11.9 Sanofi
11.9.1 Sanofi Company Details
11.9.2 Sanofi Business Overview
11.9.3 Sanofi Chromoblastomycosis Treatment Introduction
11.9.4 Sanofi Revenue in Chromoblastomycosis Treatment Business (2016-2021)
11.9.5 Sanofi Recent Development
11.10 Roche
11.10.1 Roche Company Details
11.10.2 Roche Business Overview
11.10.3 Roche Chromoblastomycosis Treatment Introduction
11.10.4 Roche Revenue in Chromoblastomycosis Treatment Business (2016-2021)
11.10.5 Roche Recent Development
11.11 Cadila Pharmaceuticals
11.11.1 Cadila Pharmaceuticals Company Details
11.11.2 Cadila Pharmaceuticals Business Overview
11.11.3 Cadila Pharmaceuticals Chromoblastomycosis Treatment Introduction
11.11.4 Cadila Pharmaceuticals Revenue in Chromoblastomycosis Treatment Business (2016-2021)
11.11.5 Cadila Pharmaceuticals Recent Development
11.12 Johnson & Johnson
11.12.1 Johnson & Johnson Company Details
11.12.2 Johnson & Johnson Business Overview
11.12.3 Johnson & Johnson Chromoblastomycosis Treatment Introduction
11.12.4 Johnson & Johnson Revenue in Chromoblastomycosis Treatment Business (2016-2021)
11.12.5 Johnson & Johnson Recent Development
11.13 Pfizer
11.13.1 Pfizer Company Details
11.13.2 Pfizer Business Overview
11.13.3 Pfizer Chromoblastomycosis Treatment Introduction
11.13.4 Pfizer Revenue in Chromoblastomycosis Treatment Business (2016-2021)
11.13.5 Pfizer Recent Development
11.14 Novartis
11.14.1 Novartis Company Details
11.14.2 Novartis Business Overview
11.14.3 Novartis Chromoblastomycosis Treatment Introduction
11.14.4 Novartis Revenue in Chromoblastomycosis Treatment Business (2016-2021)
11.14.5 Novartis Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Chromoblastomycosis Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Diagnosis
Table 3. Key Players of Treatment
Table 4. Global Chromoblastomycosis Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Chromoblastomycosis Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Chromoblastomycosis Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Chromoblastomycosis Treatment Market Share by Regions (2016-2021)
Table 8. Global Chromoblastomycosis Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Chromoblastomycosis Treatment Market Share by Regions (2022-2027)
Table 10. Chromoblastomycosis Treatment Market Trends
Table 11. Chromoblastomycosis Treatment Market Drivers
Table 12. Chromoblastomycosis Treatment Market Challenges
Table 13. Chromoblastomycosis Treatment Market Restraints
Table 14. Global Chromoblastomycosis Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Chromoblastomycosis Treatment Market Share by Players (2016-2021)
Table 16. Global Top Chromoblastomycosis Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chromoblastomycosis Treatment as of 2020)
Table 17. Ranking of Global Top Chromoblastomycosis Treatment Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Chromoblastomycosis Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Chromoblastomycosis Treatment Product Solution and Service
Table 21. Date of Enter into Chromoblastomycosis Treatment Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Chromoblastomycosis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Chromoblastomycosis Treatment Revenue Market Share by Type (2016-2021)
Table 25. Global Chromoblastomycosis Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Chromoblastomycosis Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Chromoblastomycosis Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Chromoblastomycosis Treatment Revenue Market Share by Application (2016-2021)
Table 29. Global Chromoblastomycosis Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Chromoblastomycosis Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Chromoblastomycosis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Chromoblastomycosis Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Chromoblastomycosis Treatment Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Chromoblastomycosis Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Chromoblastomycosis Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Chromoblastomycosis Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Chromoblastomycosis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Chromoblastomycosis Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Chromoblastomycosis Treatment Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Chromoblastomycosis Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Chromoblastomycosis Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Chromoblastomycosis Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Chromoblastomycosis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Chromoblastomycosis Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Chromoblastomycosis Treatment Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Chromoblastomycosis Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Chromoblastomycosis Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Chromoblastomycosis Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Chromoblastomycosis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Chromoblastomycosis Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Chromoblastomycosis Treatment Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Chromoblastomycosis Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Chromoblastomycosis Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Chromoblastomycosis Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Chromoblastomycosis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Chromoblastomycosis Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Chromoblastomycosis Treatment Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Chromoblastomycosis Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Chromoblastomycosis Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Chromoblastomycosis Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 61. Astellas Pharma Company Details
Table 62. Astellas Pharma Business Overview
Table 63. Astellas Pharma Chromoblastomycosis Treatment Product
Table 64. Astellas Pharma Revenue in Chromoblastomycosis Treatment Business (2016-2021) & (US$ Million)
Table 65. Astellas Pharma Recent Development
Table 66. Biocon Company Details
Table 67. Biocon Business Overview
Table 68. Biocon Chromoblastomycosis Treatment Product
Table 69. Biocon Revenue in Chromoblastomycosis Treatment Business (2016-2021) & (US$ Million)
Table 70. Biocon Recent Development
Table 71. Abbott Laboratories Company Details
Table 72. Abbott Laboratories Business Overview
Table 73. Abbott Laboratories Chromoblastomycosis Treatment Product
Table 74. Abbott Laboratories Revenue in Chromoblastomycosis Treatment Business (2016-2021) & (US$ Million)
Table 75. Abbott Laboratories Recent Development
Table 76. Merck Company Details
Table 77. Merck Business Overview
Table 78. Merck Chromoblastomycosis Treatment Product
Table 79. Merck Revenue in Chromoblastomycosis Treatment Business (2016-2021) & (US$ Million)
Table 80. Merck Recent Development
Table 81. Gilead Sciences Company Details
Table 82. Gilead Sciences Business Overview
Table 83. Gilead Sciences Chromoblastomycosis Treatment Product
Table 84. Gilead Sciences Revenue in Chromoblastomycosis Treatment Business (2016-2021) & (US$ Million)
Table 85. Gilead Sciences Recent Development
Table 86. Mylan Labs Company Details
Table 87. Mylan Labs Business Overview
Table 88. Mylan Labs Chromoblastomycosis Treatment Product
Table 89. Mylan Labs Revenue in Chromoblastomycosis Treatment Business (2016-2021) & (US$ Million)
Table 90. Mylan Labs Recent Development
Table 91. Bayer Company Details
Table 92. Bayer Business Overview
Table 93. Bayer Chromoblastomycosis Treatment Product
Table 94. Bayer Revenue in Chromoblastomycosis Treatment Business (2016-2021) & (US$ Million)
Table 95. Bayer Recent Development
Table 96. Lonza Group Company Details
Table 97. Lonza Group Business Overview
Table 98. Lonza Group Revenue in Chromoblastomycosis Treatment Business (2016-2021) & (US$ Million)
Table 99. Lonza Group Recent Development
Table 100. Sanofi Company Details
Table 101. Sanofi Business Overview
Table 102. Sanofi Chromoblastomycosis Treatment Product
Table 103. Sanofi Revenue in Chromoblastomycosis Treatment Business (2016-2021) & (US$ Million)
Table 104. Sanofi Recent Development
Table 105. Roche Company Details
Table 106. Roche Business Overview
Table 107. Roche Chromoblastomycosis Treatment Product
Table 108. Roche Revenue in Chromoblastomycosis Treatment Business (2016-2021) & (US$ Million)
Table 109. Roche Recent Development
Table 110. Cadila Pharmaceuticals Company Details
Table 111. Cadila Pharmaceuticals Business Overview
Table 112. Cadila Pharmaceuticals Chromoblastomycosis Treatment Product
Table 113. Cadila Pharmaceuticals Revenue in Chromoblastomycosis Treatment Business (2016-2021) & (US$ Million)
Table 114. Cadila Pharmaceuticals Recent Development
Table 115. Johnson & Johnson Company Details
Table 116. Johnson & Johnson Business Overview
Table 117. Johnson & Johnson Chromoblastomycosis Treatment Product
Table 118. Johnson & Johnson Revenue in Chromoblastomycosis Treatment Business (2016-2021) & (US$ Million)
Table 119. Johnson & Johnson Recent Development
Table 120. Pfizer Company Details
Table 121. Pfizer Business Overview
Table 122. Pfizer Chromoblastomycosis Treatment Product
Table 123. Pfizer Revenue in Chromoblastomycosis Treatment Business (2016-2021) & (US$ Million)
Table 124. Pfizer Recent Development
Table 125. Novartis Company Details
Table 126. Novartis Business Overview
Table 127. Novartis Chromoblastomycosis Treatment Product
Table 128. Novartis Revenue in Chromoblastomycosis Treatment Business (2016-2021) & (US$ Million)
Table 129. Novartis Recent Development
Table 130. Research Programs/Design for This Report
Table 131. Key Data Information from Secondary Sources
Table 132. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Chromoblastomycosis Treatment Market Share by Type: 2020 VS 2027
Figure 2. Diagnosis Features
Figure 3. Treatment Features
Figure 4. Global Chromoblastomycosis Treatment Market Share by Application: 2020 VS 2027
Figure 5. Hospitals Case Studies
Figure 6. Clinics Case Studies
Figure 7. Chromoblastomycosis Treatment Report Years Considered
Figure 8. Global Chromoblastomycosis Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 9. Global Chromoblastomycosis Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 10. Global Chromoblastomycosis Treatment Market Share by Regions: 2020 VS 2027
Figure 11. Global Chromoblastomycosis Treatment Market Share by Regions (2022-2027)
Figure 12. Global Chromoblastomycosis Treatment Market Share by Players in 2020
Figure 13. Global Top Chromoblastomycosis Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chromoblastomycosis Treatment as of 2020
Figure 14. The Top 10 and 5 Players Market Share by Chromoblastomycosis Treatment Revenue in 2020
Figure 15. Global Chromoblastomycosis Treatment Revenue Market Share by Type (2016-2021)
Figure 16. Global Chromoblastomycosis Treatment Revenue Market Share by Type (2022-2027)
Figure 17. North America Chromoblastomycosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 18. North America Chromoblastomycosis Treatment Market Share by Type (2016-2027)
Figure 19. North America Chromoblastomycosis Treatment Market Share by Application (2016-2027)
Figure 20. North America Chromoblastomycosis Treatment Market Share by Country (2016-2027)
Figure 21. United States Chromoblastomycosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. Canada Chromoblastomycosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Europe Chromoblastomycosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Chromoblastomycosis Treatment Market Share by Type (2016-2027)
Figure 25. Europe Chromoblastomycosis Treatment Market Share by Application (2016-2027)
Figure 26. Europe Chromoblastomycosis Treatment Market Share by Country (2016-2027)
Figure 27. Germany Chromoblastomycosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. France Chromoblastomycosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. U.K. Chromoblastomycosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Italy Chromoblastomycosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Russia Chromoblastomycosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Nordic Chromoblastomycosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Asia-Pacific Chromoblastomycosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Chromoblastomycosis Treatment Market Share by Type (2016-2027)
Figure 35. Asia-Pacific Chromoblastomycosis Treatment Market Share by Application (2016-2027)
Figure 36. Asia-Pacific Chromoblastomycosis Treatment Market Share by Region (2016-2027)
Figure 37. China Chromoblastomycosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Japan Chromoblastomycosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. South Korea Chromoblastomycosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Southeast Asia Chromoblastomycosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. India Chromoblastomycosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Australia Chromoblastomycosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Latin America Chromoblastomycosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Chromoblastomycosis Treatment Market Share by Type (2016-2027)
Figure 45. Latin America Chromoblastomycosis Treatment Market Share by Application (2016-2027)
Figure 46. Latin America Chromoblastomycosis Treatment Market Share by Country (2016-2027)
Figure 47. Mexico Chromoblastomycosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Brazil Chromoblastomycosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Middle East & Africa Chromoblastomycosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Chromoblastomycosis Treatment Market Share by Type (2016-2027)
Figure 51. Middle East & Africa Chromoblastomycosis Treatment Market Share by Application (2016-2027)
Figure 52. Middle East & Africa Chromoblastomycosis Treatment Market Share by Country (2016-2027)
Figure 53. Turkey Chromoblastomycosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Saudi Arabia Chromoblastomycosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. UAE Chromoblastomycosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Astellas Pharma Revenue Growth Rate in Chromoblastomycosis Treatment Business (2016-2021)
Figure 57. Biocon Revenue Growth Rate in Chromoblastomycosis Treatment Business (2016-2021)
Figure 58. Abbott Laboratories Revenue Growth Rate in Chromoblastomycosis Treatment Business (2016-2021)
Figure 59. Merck Revenue Growth Rate in Chromoblastomycosis Treatment Business (2016-2021)
Figure 60. Gilead Sciences Revenue Growth Rate in Chromoblastomycosis Treatment Business (2016-2021)
Figure 61. Mylan Labs Revenue Growth Rate in Chromoblastomycosis Treatment Business (2016-2021)
Figure 62. Bayer Revenue Growth Rate in Chromoblastomycosis Treatment Business (2016-2021)
Figure 63. Lonza Group Revenue Growth Rate in Chromoblastomycosis Treatment Business (2016-2021)
Figure 64. Sanofi Revenue Growth Rate in Chromoblastomycosis Treatment Business (2016-2021)
Figure 65. Roche Revenue Growth Rate in Chromoblastomycosis Treatment Business (2016-2021)
Figure 66. Cadila Pharmaceuticals Revenue Growth Rate in Chromoblastomycosis Treatment Business (2016-2021)
Figure 67. Johnson & Johnson Revenue Growth Rate in Chromoblastomycosis Treatment Business (2016-2021)
Figure 68. Pfizer Revenue Growth Rate in Chromoblastomycosis Treatment Business (2016-2021)
Figure 69. Novartis Revenue Growth Rate in Chromoblastomycosis Treatment Business (2016-2021)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed

Global Chromoblastomycosis Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z1309 2021年4月 91Pages
QYResearch社発行の本調査資料では、クロモブラストミコーシス（CBM）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（診断、治療）、用途別市場規模（病院、クリニック）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中...

世界の急性間欠性ポルフィリン症（AIP）治療市場規模・現状・予測（2021年-2027年）

Global Acute Intermittent Porphyria Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z0060 2021年4月 92Pages
QYResearch社発行の本調査資料では、急性間欠性ポルフィリン症（AIP）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（350mg、313mg）、用途別市場規模（病院、薬局）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日...

世界のアデノシンデアミナーゼ欠損症（ADA）治療市場規模・現状・予測（2021年-2027年）

Global Adenosine Deaminase Deficiency Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z0096 2021年4月 96Pages
QYResearch社発行の本調査資料では、アデノシンデアミナーゼ欠損症（ADA）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（アダーゲン、レブコビ）、用途別市場規模（病院、薬局）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、...

世界の神経精神障害＆治療市場規模・現状・予測（2021年-2027年）

Global Neuropsychiatric Disorders and Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z4097 2021年4月 97Pages
QYResearch社発行の本調査資料では、神経精神障害＆治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（薬物治療、ショック治療、その他）、用途別市場規模（病院、診療所、研究センター）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア...

世界の神経性食欲不振症（AN）治療市場規模・現状・予測（2021年-2027年）

Global Anorexia Nervosa Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z0355 2021年4月 94Pages
QYResearch社発行の本調査資料では、神経性食欲不振症（AN）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（心理療法、薬理療法、その他）、用途別市場規模（病院、クリニック、在宅医療、その他）、主要地域別市場規模（北米、アメリカ、ヨー...

世界の顕微鏡的多発血管炎（MPA）治療市場規模・現状・予測（2021年-2027年）

Global Microscopic Polyangiitis (MPA) Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z3776 2021年4月 98Pages
QYResearch社発行の本調査資料では、顕微鏡的多発血管炎（MPA）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（アバコパン、免疫グロブリン、リツキシマブバイオシミラー、その他）、用途別市場規模（病院、クリニック、その他）、主要地域別...

世界の髄膜炎診断・治療市場規模・現状・予測（2021年-2027年）

Global Meningitis Diagnosis and Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z3698 2021年4月 95Pages
QYResearch社発行の本調査資料では、髄膜炎診断・治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（ウイルス性髄膜炎、細菌性髄膜炎、その他）、用途別市場規模（病院・クリニック、診断センター）、主要地域別市場規模（北米、アメリカ、ヨーロッ...

世界のHIV診断＆治療市場規模・現状・予測（2021年-2027年）

Global HIV Diagnosis & Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z2855 2021年4月 90Pages
QYResearch社発行の本調査資料では、HIV診断＆治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（ELISA検査、唾液検査、ウイルス量検査、ウエスタンブロット、その他）、用途別市場規模（病院、クリニック）、主要地域別市場規模（北米、ア...

世界の再発性多形性膠芽腫（GBM）治療市場規模・現状・予測（2021年-2027年）

Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z4963 2021年4月 91Pages
QYResearch社発行の本調査資料では、再発性多形性膠芽腫（GBM）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（経口薬、テモゾロミド、放射線増感剤、ニトロソウレア薬、放射線療法、化学療法）、用途別市場規模（病院、診療所、外来手術セン...

世界の経口血糖降下薬（OAD）治療市場規模・現状・予測（2021年-2027年）

Global Oral Antidiabetic (OAD) Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z4299 2021年4月 92Pages
QYResearch社発行の本調査資料では、経口血糖降下薬（OAD）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（スルホニル尿素剤、ビグアニド、腸内α-グルコシダーゼ阻害剤、その他）、用途別市場規模（病院、診療所、糖尿病治療センター、その...

世界のクロモブラストミコーシス（CBM）治療市場規模・現状・予測（2021年-2027年） Chromoblastomycosis is a fungal infection caused by species such as Fonsecaea pedrosoi, Cladophialophora carrionii, Phialophora verrucosa, Fonsecaea compacta, Rhinocladiella aquaspersa, Chaetomium funicola and others. This disease mostly affects the skin and the subcutaneous tissues. Globally, there…
世界の髄膜炎診断・治療市場規模・現状・予測（2021年-2027年） Meningitis is an acute inflammation of the protective membranes covering the brain and spinal cord, known collectively as the meninges. The most common symptoms are fever, headache, and neck stiffness. Other symptoms include confusion or altered consciousness, vomiting, and an inability to tolerate …
世界のHIV診断＆治療市場規模・現状・予測（2021年-2027年） HIV prevalence in Africa, specifically in Southern region is very high as compared to North African region. Approximately 1 out of 4 is suffering from HIV. Southern and Eastern region of Africa has one of the highest prevalence rate of HIV, about 19 million people have HIV. While HIV prevalence is l…
世界のHIV診断・治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global HIV Diagnosis and Treatment Market The global HIV Diagnosis and Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity…
世界のてんかん診断・治療市場規模・現状・予測（2021年-2027年） Epilepsy is a neurological disorder affecting the central nervous system. In this medical condition, the brain exhibits abnormal activity, which results in periods of unusual behavior or seizures and sometimes, loss of awareness. Temporary confusion, anxiety, uncontrollable jerking movements of the …